BridgeBio Q4 revenue jumps on Attruby sales

Reuters

02/25

BridgeBio Q4 revenue jumps on Attruby sales

Overview

Biopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product sales
Company reported positive Phase 3 trial results for multiple drugs
Company issued $632.5 mln convertible notes to fund operations

Outlook

BridgeBio plans NDA submission for BBP-418 in 1H 2026, U.S. launch late 2026/early 2027
Company expects NDA submission for encaleret in 1H 2026, U.S. launch late 2026/early 2027
BridgeBio anticipates NDA submission for infigratinib in 2H 2026, launch early to mid 2027

Result Drivers

ATTRUBY SALES - Attruby net product revenue increased by 35% quarter-over-quarter, driven by its differentiated profile and continued prescribing growth
FINANCIAL POSITION - Issuance of $632.5 mln convertible notes in January 2026 to fund planned commercial and pipeline operations

Company press release: ID:nGNX8qbj9j

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$194.64 mln
Q4 Operating Income		-$139.56 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for BridgeBio Pharma Inc is $96.00, about 41.4% above its February 23 closing price of $67.91

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614728821"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614728821\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614728821?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614728821","market":"us","top_or_hot":-1,"title":"BridgeBio Q4 revenue jumps on Attruby sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BridgeBio Q4 revenue jumps on Attruby sales</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product sales</p></li><li><p>Company reported positive Phase 3 trial results for multiple drugs</p></li><li><p>Company issued $632.5 mln convertible notes to fund operations</p></li></ul><p><span>Outlook</span></p><ul><li><p>BridgeBio plans NDA submission for BBP-418 in 1H 2026, U.S. launch late 2026/early 2027</p></li><li><p>Company expects NDA submission for encaleret in 1H 2026, U.S. launch late 2026/early 2027</p></li><li><p>BridgeBio anticipates NDA submission for infigratinib in 2H 2026, launch early to mid 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ATTRUBY SALES - Attruby net product revenue increased by 35% quarter-over-quarter, driven by its differentiated profile and continued prescribing growth</p></li><li><p>FINANCIAL POSITION - Issuance of $632.5 mln convertible notes in January 2026 to fund planned commercial and pipeline operations</p></li></ul><p>Company press release: <span>ID:nGNX8qbj9j</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$194.64 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$139.56 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 22 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc is $96.00, about 41.4% above its February 23 closing price of $67.91</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Q4 revenue jumps on Attruby sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Q4 revenue jumps on Attruby sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-25 05:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BridgeBio Q4 revenue jumps on Attruby sales</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product sales</p></li><li><p>Company reported positive Phase 3 trial results for multiple drugs</p></li><li><p>Company issued $632.5 mln convertible notes to fund operations</p></li></ul><p><span>Outlook</span></p><ul><li><p>BridgeBio plans NDA submission for BBP-418 in 1H 2026, U.S. launch late 2026/early 2027</p></li><li><p>Company expects NDA submission for encaleret in 1H 2026, U.S. launch late 2026/early 2027</p></li><li><p>BridgeBio anticipates NDA submission for infigratinib in 2H 2026, launch early to mid 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ATTRUBY SALES - Attruby net product revenue increased by 35% quarter-over-quarter, driven by its differentiated profile and continued prescribing growth</p></li><li><p>FINANCIAL POSITION - Issuance of $632.5 mln convertible notes in January 2026 to fund planned commercial and pipeline operations</p></li></ul><p>Company press release: <span>ID:nGNX8qbj9j</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$194.64 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$139.56 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 22 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma</a> Inc is $96.00, about 41.4% above its February 23 closing price of $67.91</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4149","symbol_name":"建築機械與重型卡車","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZK1A6:1","article_id":"2614728821","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614728821","pubTimestamp":1771967382,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Q4 revenue jumps on Attruby salesOverviewBiopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product salesCompany reported positive Phase 3 trial results for multipl","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4149":"建筑机械与重型卡车","BK4588":"碎股","BK4567":"ESG概念","BBIO":"BridgeBio Pharma, Inc.","BK4505":"高瓴资本持仓","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","CMI":"康明斯","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"BridgeBio第四季度收入因Attruby销售而猛增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"BBIO":0.9},"content_text":"BridgeBio Q4 revenue jumps on Attruby salesOverviewBiopharmaceutical company's Q4 revenue rose significantly, driven by Attruby product salesCompany reported positive Phase 3 trial results for multiple drugsCompany issued $632.5 mln convertible notes to fund operationsOutlookBridgeBio plans NDA submission for BBP-418 in 1H 2026, U.S. launch late 2026/early 2027Company expects NDA submission for encaleret in 1H 2026, U.S. launch late 2026/early 2027BridgeBio anticipates NDA submission for infigratinib in 2H 2026, launch early to mid 2027Result DriversATTRUBY SALES - Attruby net product revenue increased by 35% quarter-over-quarter, driven by its differentiated profile and continued prescribing growthFINANCIAL POSITION - Issuance of $632.5 mln convertible notes in January 2026 to fund planned commercial and pipeline operationsCompany press release: ID:nGNX8qbj9jKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Net Income-$194.64 mlnQ4 Operating Income-$139.56 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 22 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for BridgeBio Pharma Inc is $96.00, about 41.4% above its February 23 closing price of $67.91For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}